Cytel Company Profile - pharmaphorum

Editions

Contact

1. Cover
2. Introduction
3. Contents
4. Why pharma needs honest patient dialogue
5. Did cancer clinical trials stay on track at ASCO 2019?
6. Getting patients round the virtual table
7. Sign-up for pharma news alerts
8. Cytel Company Profile
9. Adapting for the future of oncology trials
10. Revealing the true value of new cancer drugs
11. Discover the power of strategic partnerships
12. Smarter thinking about pharma marketing
13. Moving from autologous to allogeneic ACT
14. The promise and pitfalls of molecular testing
15. Subscribe to future Deep Dive issues
16. Contact the Deep Dive team

Open magazine

Editions

Contact

Hi there!

Click here and sign up now

Adapting for the Future of Oncology Trials

Read article

Company Spotlight

Accolades

Designed and implemented more adaptive trials than any other organisation
East trial design software used by regulatory agencies
2018 Scrip Awards Winner – Best CRO Specialist Provider
2017 CARE Awards Winner – Most Innovative Trial Design (in collaboration with TRACON Pharmaceuticals)
Finalists in 2016 and 2018 at the Scrip Awards for Best sponsor-focused technological development

Year established

1987

Geographic reach

Headquartered in Cambridge, Massachusetts, Cytel serves a global portfolio of biopharmaceutical and medical device companies from its 14 offices in the US, Europe and India

Company goal and ideology

To turn clinical and real-world data into evidence to minimise risk and accelerate the development of promising new medicines

Core areas of expertise

Advanced analytical services and technologies to advance the development of new medicines

Video

Your name

Your e-mail

Name receiver

E-mail address receiver

Your message

Cancel

Send

E-mail

Facebook

Twitter

Contact

Your name Your e-mail Your message

Cancel

Send